CSIMarket
 


Nektar Therapeutics  (NKTR)
Other Ticker:  
 
 

NKTR's Revenue Growth by Quarter and Year

Nektar Therapeutics's Revenue results by quarter and year




NKTR Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 22.02 25.01 30.03
III Quarter September 24.14 23.63 24.92 48.85
II Quarter June 20.50 21.59 28.33 50.57
I Quarter March 21.59 24.82 23.65 33.86
FY   66.23 92.06 101.91 163.31



NKTR Revenue third quarter 2023 Y/Y Growth Comment
Nektar Therapeutics reported Revenue growth of 2.18% year on year in the third quarter 2023, to $ 24.14 millions, this is lower than Nektar Therapeutics's recent average Revenue rise of 59.61%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Revenue growth. While Nektar Therapeutics' s Revenue increase of 2.18% ranks overall at the positon no. 1493 in the third quarter 2023.




NKTR Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -11.96 % -16.72 % 2.77 %
III Quarter September 2.18 % -5.18 % -48.99 % 109.48 %
II Quarter June -5.05 % -23.79 % -43.98 % 79.2 %
I Quarter March -13.01 % 4.95 % -30.15 % -14.99 %
FY   - -9.67 % -37.6 % 35.43 %

Financial Statements
Nektar Therapeutics's third quarter 2023 Revenue $ 24.14 millions NKTR's Income Statement
Nektar Therapeutics's third quarter 2022 Revenue $ 23.63 millions Quarterly NKTR's Income Statement
New: More NKTR's historic Revenue Growth >>


NKTR Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -6.81 % 0.36 % -38.53 %
III Quarter September 17.78 % 9.45 % -12.04 % -3.4 %
II Quarter June -5.05 % -13.01 % 19.79 % 49.35 %
I Quarter March -1.95 % -0.76 % -21.25 % 15.88 %
FY (Year on Year)   - -9.67 % -37.6 % 35.43 %




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #224
Overall #1493

Revenue Y/Y Growth Statistics
High Average Low
932.38 % 59.61 % -91.33 %
(Jun 30 2018)   (Jun 30 2019)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #224
Overall #1493
Revenue Y/Y Growth Statistics
High Average Low
932.38 % 59.61 % -91.33 %
(Jun 30 2018)   (Jun 30 2019)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Nektar Therapeutics's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2761.06 % 88.5 % -97.45 %
(Jun 30 2018)  


NKTR's III. Quarter Q/Q Revenue Comment
Nektar Therapeutics achieved in the III. Quarter 2023 below company average Revenue jump of 17.78% quarter on quarter, to $ 24.14 millions.

Albeit the III. Quarter 2023 NKTR's results were lower than the average , that was yet encouraging sign, as the current surge, outshines the 9.45% surge in the same quarter a year ago

Within Major Pharmaceutical Preparations industry 79 other companies have achieved higher Revenue quarter on quarter growth. While Nektar Therapeutics's Revenue growth quarter on quarter, overall rank is 526.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #80
Healthcare Sector #161
Overall #526
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #80
Healthcare Sector #161
Overall #526
Revenue Q/Q Growth Statistics
High Average Low
2761.06 % 88.5 % -97.45 %
(Jun 30 2018)  


NKTR's III. Quarter Q/Q Revenue Comment
Nektar Therapeutics achieved in the III. Quarter 2023 below company average Revenue jump of 17.78% quarter on quarter, to $ 24.14 millions.

III. Quarter 2023 NKTR's Revenue sequential growth appear to be paradoxical, albeit beneath the ordinary growth of 88.5 %, yet it presents a quite improvement measured to the 9.45% in the III. Quarter 2022.

Within Major Pharmaceutical Preparations industry 79 other companies have achieved higher Revenue quarter on quarter growth. While Nektar Therapeutics's Revenue growth quarter on quarter, overall rank is 526.


Nektar Therapeutics's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 88.26 $ 87.74 $ 88.83 $ 92.06 $ 95.04
Y / Y Revenue Growth (TTM) -7.13 % -8.92 % -13.83 % -9.67 % -11.12 %
Year on Year Revenue Growth Overall Ranking # 1815 # 2422 # 2535 # 3071 # 2553
Seqeuential Revenue Change (TTM) 0.59 % -1.22 % -3.51 % -3.14 % -1.35 %
Seq. Revenue Growth (TTM) Overall Ranking # 1493 # 2084 # 2315 # 2598 # 2597




Cumulative Revenue growth Comment
Nektar Therapeutics showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Nektar Therapeutics's annual Revenue decline would be -7.13% year on year to $88 millions.

In the Healthcare sector 258 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1815, from total ranking in previous quarter at 2422.

Revenue TTM Q/Q Growth Statistics
High Average Low
932.38 %
59.61 %
-91.33 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 259
Overall # 1815

Revenue TTM Y/Y Growth Statistics
High Average Low
932.38 %
59.61 %
-91.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 77
Sector # 224
S&P 500 # 1493
Cumulative Revenue growth Comment
Nektar Therapeutics showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Nektar Therapeutics's annual Revenue drop would be -7.13% year on year to $88 millions.

In the Healthcare sector 258 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1815, from total ranking in previous quarter at 2422.

Revenue TTM Q/Q Growth Statistics
High Average Low
932.38 %
59.61 %
-91.33 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 259
Overall # 1815

Revenue TTM Y/Y Growth Statistics
High Average Low
932.38 %
59.61 %
-91.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 77
Sector # 224
S&P 500 # 1493




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NKTR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for NKTR's Competitors
Revenue Growth for Nektar Therapeutics's Suppliers
Revenue Growth for NKTR's Customers

You may also want to know
NKTR's Annual Growth Rates NKTR's Profitability Ratios NKTR's Asset Turnover Ratio NKTR's Dividend Growth
NKTR's Roe NKTR's Valuation Ratios NKTR's Financial Strength Ratios NKTR's Dividend Payout Ratio
NKTR's Roa NKTR's Inventory Turnover Ratio NKTR's Growth Rates NKTR's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Charles River Laboratories International inc 3.79%$ 3.788 millions
Amgen Inc 3.77%$ 3.773 millions
Owens and Minor inc3.77%$ 3.768 millions
Sight Sciences Inc 3.51%$ 3.507 millions
Pediatrix Medical Group Inc 3.41%$ 3.408 millions
Halozyme Therapeutics Inc 3.38%$ 3.377 millions
Jazz Pharmaceuticals Plc3.35%$ 3.347 millions
Henry Schein Inc3.10%$ 3.097 millions
Nevro Corp 3.04%$ 3.036 millions
Cv Sciences Inc 2.45%$ 2.453 millions
Bio techne Corp2.45%$ 2.447 millions
Cardiff Lexington Corporation2.30%$ 2.302 millions
Nektar Therapeutics2.20%$ 2.197 millions
Community Health Systems Inc 2.02%$ 2.017 millions
Anika Therapeutics Inc 1.69%$ 1.689 millions
Emmaus Life Sciences Inc 1.60%$ 1.600 millions
Brookdale Senior Living Inc 1.58%$ 1.576 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com